Screener
Veradermics MANE Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands, except share and per share amounts) | As of March 31, 2026 | As of December 31, 2025 |
|---|---|---|
| Accrued expenses | 5,606 | 6,979 |
| Other current liabilities and lease liabilities | 39 | 47 |
| Total current liabilities | 6,716 | 9,152 |
| Lease liabilities - non-current | — | 4 |
| Total liabilities | 6,716 | 9,156 |
| Commitments and contingencies (Note 8) | ||
| Redeemable convertible preferred stock: | ||
| Series A preferred stock, $0.00001 par value, 12,865,375 shares authorized, issued and outstanding with an aggregate liquidation preference of $37,238 as of December 31, 2025, net of issuance costs | — | 36,860 |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's operating lease liabilities?
- Veradermics (MANE) reported operating lease liabilities of $0 in Q1 2026.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Veradermics's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude